Shelley Aldred is the founder of Rondo Therapeutics. Rondo Therapeutics has raised $67M in total funding. Latest round: Series A.
Shelley Aldred is the co-founder and chief executive officer of Rondo Therapeutics, a biopharmaceutical company focused on developing next-generation immuno-oncology platforms for treating solid tumors. The company closed an oversubscribed $67 million Series A financing round in March 2022. Aldred is a repeat entrepreneur with deep expertise in bispecific antibody discovery, having co-founded and led multiple successful biotechnology companies.
Full founder directory · Investor directory · Company funding database · Fundraising library